Referências bibliográficas:
1. Hyalufem® - embalagem do produto 2. Sinha A, Ewies AA. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric. 2013 Jun;16(3):305-12. doi:10.3109/13697137.2012.756466. Epub 2013 Jan 8. 3. SILVA, A. V A.; FONSECA, S. G. C.; ARRAIS, P. S. D; FRANCELINO, E. V. Presença de Excipiente com Potencial para Indução de Reações Adversas em Medicamentos Comercializados no Brasil. Revista Brasileira de Ciências Farmacêuticas, Ceará, v.44, n.3, 2008. 4. Chen J et al. Evaluation of the Efficacy and Safety of Hyaluronic Acid Vaginal Gel to Ease Vaginal Dryness: A Multicenter, Randomized,Controlled, Open-Label, Parallel-Group, Clinical Trial. J Sex Med 2013;10:1575–1584. 5. Lui Filho JF, Baccaro LF, Fernandes t et al. Factors associated with menopausal symptoms in women from a metropolitan regions in Southeastern Brazil: a population-based household survey, Rev Bras Ginecol Obstet 2015 Apr; 37(4):152-8. 6. Agarwal SK, Kim J, Korst LM, Hughes CL. Application of the Estrogen Threshold Hypothesis to the physiologic hypoestrogenemia of lactation. Breastfeed Med 015;10:77–83. Breastfeed Med. 2015 Mar;10(2):77-83. doi: 10.1089/bfm.2014.0030. Epub 2015 Jan 7. Lammerink EA, de Bock GH, Schröder CP, Mourits MJ. The management of menopausal symptoms in breast cancer survivors: case-based approach. Maturitas. 2012 Nov;73(3):265-8. doi: 10.1016/j.maturitas.2012.07.010. Epub 2012 Aug 9. 8. Serati M, Bogani G, Di Dedda MC, et. al. A comparison between vaginal estrogen and vaginal hyaluronic for the treatment of dyspareunia in women using hormonal contraceptive. Eur J Obstet Gynecol Reprod Biol. 2015 Aug;191:48-50. doi: 10.1016/j.ejogrb.2015.05.026. Epub 2015 Jun 3. 9. Mac Bride M et al. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87-94. 10. Ghumman S. Atrophic vaginitis: Diagnosis and treatment. J South Asian Feder Menopause Soc 2013;1(1):4-12. 11. Gass, MLS et al. POSITION STATEMENT-Management of symptomatic vulvovaginal atrophy: 2013 Menopause, Vol. 20, No. 9, 2013. 12. Jokar A, Davari T, Asaldi N et al. Comparison of the Hyaluronic Acid Vaginal Cream and Conjugated Estrogen used in the treatment of vaginal Atrophy of Menopausal Women: A Randomized Controlled Clinical Trial. Int J Community Based Nurs Midwifery 2016; 4 (1): 69-78. Material destinado ao público em geral. Setembro de 2019 . 13. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause: The Journal of The North American Menopause Society 2013; 20(9): 888-902 DOI: 10.1097/gme.0b013e3182a122c2
|
Referências bibliográficas:
1. Hyalufem® - embalagem do produto 2. Sinha A, Ewies AA. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric. 2013 Jun;16(3):305-12. doi:10.3109/13697137.2012.756466. Epub 2013 Jan 8. 3. SILVA, A. V A.; FONSECA, S. G. C.; ARRAIS, P. S. D; FRANCELINO, E. V. Presença de Excipiente com Potencial para Indução de Reações Adversas em Medicamentos Comercializados no Brasil. Revista Brasileira de Ciências Farmacêuticas, Ceará, v.44, n.3, 2008. 4. Chen J et al. Evaluation of the Efficacy and Safety of Hyaluronic Acid Vaginal Gel to Ease Vaginal Dryness: A Multicenter, Randomized,Controlled, Open-Label, Parallel-Group, Clinical Trial. J Sex Med 2013;10:1575–1584. 5. Lui Filho JF, Baccaro LF, Fernandes t et al. Factors associated with menopausal symptoms in women from a metropolitan regions in Southeastern Brazil: a population-based household survey, Rev Bras Ginecol Obstet 2015 Apr; 37(4):152-8. 6. Agarwal SK, Kim J, Korst LM, Hughes CL. Application of the Estrogen Threshold Hypothesis to the physiologic hypoestrogenemia of lactation. Breastfeed Med 015;10:77–83. Breastfeed Med. 2015 Mar;10(2):77-83. doi: 10.1089/bfm.2014.0030. Epub 2015 Jan 7. Lammerink EA, de Bock GH, Schröder CP, Mourits MJ. The management of menopausal symptoms in breast cancer survivors: case-based approach. Maturitas. 2012 Nov;73(3):265-8. doi: 10.1016/j.maturitas.2012.07.010. Epub 2012 Aug 9. 8. Serati M, Bogani G, Di Dedda MC, et. al. A comparison between vaginal estrogen and vaginal hyaluronic for the treatment of dyspareunia in women using hormonal contraceptive. Eur J Obstet Gynecol Reprod Biol. 2015 Aug;191:48-50. doi: 10.1016/j.ejogrb.2015.05.026. Epub 2015 Jun 3. 9. Mac Bride M et al. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87-94. 10. Ghumman S. Atrophic vaginitis: Diagnosis and treatment. J South Asian Feder Menopause Soc 2013;1(1):4-12. 11. Gass, MLS et al. POSITION STATEMENT-Management of symptomatic vulvovaginal atrophy: 2013 Menopause, Vol. 20, No. 9, 2013. 12. Jokar A, Davari T, Asaldi N et al. Comparison of the Hyaluronic Acid Vaginal Cream and Conjugated Estrogen used in the treatment of vaginal Atrophy of Menopausal Women: A Randomized Controlled Clinical Trial. Int J Community Based Nurs Midwifery 2016; 4 (1): 69-78. Material destinado ao público em geral. Setembro de 2019 . 13. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause: The Journal of The North American Menopause Society 2013; 20(9): 888-902 DOI: 10.1097/gme.0b013e3182a122c2
|
|